Products for Research Use Only
RegisterLogin

Rel-Lifirafenib

CAT: 0804-HY-18957ASize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-18957ASize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Rel-Lifirafenib (rel-BGB-283) is the relative configuration of Lifirafenib. Lifirafenib is a potent Raf Kinase and EGFR inhibitor[1].
CAS Number
1446090-77-2
Product Name Alternative
Rel-BGB-283
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
EGFR; Raf
Type
Reference compound
Related Pathways
JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/rel-lifirafenib.html
Solubility
10 mM in DMSO
Smiles
O=C1NC2=NC=CC(OC3=CC=C(O[C@]4([H])[C@@]5([H])[C@H]4C6=NC7=CC=C(C(F)(F)F)C=C7N6)C5=C3)=C2CC1.[Relativestereochemistry]
Molecular Formula
C25H17F3N4O3
Molecular Weight
478.42
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Tang Z, et al. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers. Mol Cancer Ther. 2015 Oct;14 (10) :2187-97.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-18957-01Lifirafenib
HY-18957CLifirafenib (hydrochloride)
HY-18957BLifirafenib (maleate)
HY-I1031-01Rel-Bedaquiline
HY-18295A-01Rel-Erteberel
HY-114163ARel-ML123
HY-15322A(rel) -PRT062607
HY-106874BRel-Delequamine
HY-124874(rel) -Asperparaline A
HY-N0608B(rel)-Myrislignan

Alternative Products

CatalogName
T22272-01Lifirafenib
A20988-5Lifirafenib 5mg
T86810-01Lifirafenib maleate
MBS5812528Lifirafenib HCl
A20988-100Lifirafenib 100mg
A20988-50Lifirafenib 50mg
A20988-10Lifirafenib 10mg
C13058-01Lifirafenib (BGB-283)
A16844-50Lifirafenib (BGB-283) 50mg
584437Lifirafenib free base

Popular Products